Securities Claims Against Drug Maker Dismissed For Failure To Plead Scienter

(October 20, 2017, 2:48 PM EDT) -- SEATTLE — The lead plaintiff in a securities class action against a developmental stage biopharmaceutical company and certain of its executive officers has shown that the defendants misrepresented the success and...
To view the full article, register now.